APOE4 heterozygous women exhibit a 4-fold increased risk of AD, while both men and women homozygous carriers exhibit a 12–15-fold increased risk of AD compared to non-carriers (Payami et al., 1994; Mortensen and Hogh, 2001; Beydoun et al., 2012). Here, APOE is linked to Alzheimer disease.